Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol Enhanced Hippocampal Vascular Imaging in Epilepsy
NCT06483061Phase 2Recruiting
- Sponsor
- University of Alberta
- Start
- May 2025
- Primary completion
- Sep 2029
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ferumoxytol in temporal lobe epilepsy (TLE), sponsored by University of Alberta. Primary endpoint: Ferumoxytol enhanced cerebral vasculature imaging. Started May 2025; status: recruiting.
02
Drugs
ferumoxytol
03
Conditions
temporal lobe epilepsy (TLE)
Beyond the preview
Go deeper on NCT06483061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06483061.